Overview

A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered

Status:
Completed
Trial end date:
2017-07-24
Target enrollment:
Participant gender:
Summary
To evaluate the relative bioavailability of ticagrelor for the different formulations. A randomized cross-over design has been chosen to minimize the effects of between-subject variability and any period effects on the overall results.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Parexel
Treatments:
Platelet Aggregation Inhibitors
Ticagrelor